Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO): Study Protocol for an Open-label Prospective Phase II Umbrella Clinical Trial

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Mar 11

PMID 40065286

Authors

Haichao Huang

Tao Wang

Wei Li

Zhun Wu

Xuegang Wang

Jinchun Xing

Bin Chen

Kaiyan Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The management of locally advanced prostate cancer (PCa) and oligometastatic prostate cancer (OMPCa) remains a clinical challenge. The heterogeneous nature of PCa prompts a need for precision treatment. This study aims to verify whether genomic biomarker-guided neoadjuvant therapy for locally advanced PCa and OMPCa can result in an improvement in the pathological responses and survival outcomes in a Chinese population.

Methods: In this open-label prospective phase II umbrella clinical trial, 40 patients will be enrolled. Next-generation sequencing data analysis of PCa tissues from the diagnostic needle biopsies will be performed. The genomically evaluable patients will be divided into 4 groups on the basis of genomic testing results, and receive 6 cycles of patient-tailored neoadjuvant systemic therapy targeted to alternative molecular pathways (including parmiparib, cisplatin, tislelizumab or docetaxel, respectively), and both in combination with rezvilutamide and goserelin microspheres. The primary endpoint is the rate of pathologic complete response. Secondary endpoints include rates of clinical complete response and pathological minimal residual disease (defined as residual tumor 5 mm or less), overall survival, progression-free survival and safety outcomes.

Discussion: SEGNO, to the best of our knowledge, is the first umbrella clinical trial designed to provide high-level evidence to support the implementation of genomic biomarker-guided neoadjuvant therapy for locally advanced PCa and OMPCa.

Trial Registration: Clinicaltrial.gov, NCT06387056.

References

McKay R, Ye H, Xie W, Lis R, Calagua C, Zhang Z . Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. J Clin Oncol. 2019; 37(11):923-931. PMC: 7051849. DOI: 10.1200/JCO.18.01777. View

McKay R, Berchuck J, Kwak L, Xie W, Silver R, Bubley G . Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. J Urol. 2021; 205(6):1689-1697. DOI: 10.1097/JU.0000000000001632. View

Sowalsky A, Ye H, Bhasin M, Van Allen E, Loda M, Lis R . Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018; 78(16):4716-4730. PMC: 6095796. DOI: 10.1158/0008-5472.CAN-18-0610. View

Lee L, Sim A, Ong C, Yang X, Ng C, Liu W . NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022; 25(4):741-748. PMC: 9705244. DOI: 10.1038/s41391-022-00496-8. View

Graham L, True L, Gulati R, Schade G, Wright J, Grivas P . Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer. Prostate. 2021; 81(7):418-426. PMC: 8044035. DOI: 10.1002/pros.24118. View

Chi C, Liu J, Fan L, Zhu Y, Wang Y, Sha J . Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations. Ther Adv Med Oncol. 2022; 14:17588359221128356. PMC: 9527989. DOI: 10.1177/17588359221128356. View

Thalgott M, Horn T, Heck M, Maurer T, Eiber M, Retz M . Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol. 2014; 7:20. PMC: 3974001. DOI: 10.1186/1756-8722-7-20. View

Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L . Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021; 18(12):739-762. DOI: 10.1038/s41585-021-00514-9. View

Kent E, Hussain M . Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective. Rev Urol. 2006; 5 Suppl 3:S28-37. PMC: 1502344. View

10.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384(9938):164-72. DOI: 10.1016/S0140-6736(13)62422-8. View

11.

McKay R, Xie W, Ye H, Fennessy F, Zhang Z, Lis R . Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol. 2021; 206(1):80-87. PMC: 9807004. DOI: 10.1097/JU.0000000000001702. View

12.

Chen Y, Qin J, Wu Y, Lin Q, Wang J, Zhang W . Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis. Int J Surg. 2023; 109(9):2794-2807. PMC: 10498860. DOI: 10.1097/JS9.0000000000000496. View

13.

Ku S, Gleave M, Beltran H . Towards precision oncology in advanced prostate cancer. Nat Rev Urol. 2019; 16(11):645-654. PMC: 6858516. DOI: 10.1038/s41585-019-0237-8. View

14.

Pan J, Chi C, Qian H, Zhu Y, Shao X, Sha J . Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study. Urol Oncol. 2019; 37(12):991-998. DOI: 10.1016/j.urolonc.2019.07.009. View

15.

Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M . Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. JAMA Oncol. 2022; 8(11):1668-1675. DOI: 10.1001/jamaoncol.2022.3755. View

16.

Chi C, Fan L, Dong B, Zhu Y, Xin Z, Pan J . Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis. Clin Genitourin Cancer. 2021; 19(4):e223-e234. DOI: 10.1016/j.clgc.2021.02.004. View

17.

Qian H, Chi C, Tricard T, Zhu Y, Dong L, Wang Y . A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy. J Urol. 2024; 211(5):648-655. DOI: 10.1097/JU.0000000000003876. View

18.

Taplin M, Montgomery B, Logothetis C, Bubley G, Richie J, Dalkin B . Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014; 32(33):3705-15. PMC: 4226804. DOI: 10.1200/JCO.2013.53.4578. View

19.

Mostaghel E, Nelson P . Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008; 22(2):243-58. PMC: 2474812. DOI: 10.1016/j.beem.2008.01.003. View

20.

Narita S, Nara T, Kanda S, Numakura K, Saito M, Inoue T . Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis. Clin Genitourin Cancer. 2018; 17(1):e113-e122. DOI: 10.1016/j.clgc.2018.09.019. View